Practice Management

Healthcare Trends for 2018

F. Randy Vogenberg, PhD, FASHP, John Santilli, MBA

F. Randy Vogenberg, PhD, RPh; John Santilli, MBA

The Effects of a Sitagliptin Formulary Restriction Program on Diabetes Medication Use

Yuexin Tang, PhD, Xingyue Huang, PhD, Jinan Liu, PhD, R. Ravi Shankar, MD, Michael L. Ganz, PhD, Swapnil Rajpathak, MD, DrPH

Yuexin Tang, PhD; Xingyue Huang, PhD; Jinan Liu, PhD; R. Ravi Shankar MD; Michael L. Ganz, PhD; Swapnil Rajpathak, MD, DrPH

Stakeholder Perspective

Impact of Step Therapy Restrictions in Diabetes Care

Quang T. Nguyen, DO, FACP, FACE, FTOS

by Quang T. Nguyen, DO, FACE, FTOS

Practice Management

Comparing the Medicaid Retrospective Drug Utilization Review Program Cost-Savings Methods Used by State Agencies

Sergio I. Prada, MPA, PhD

Stakeholder Perspective

Is the Federal Drug Utilization Review Requirement Just Red Tape or an Enlightened State of Flexibility?

Michael Kleinrock

by Michael Kleinrock

Original Research, Practice Management

Comparing the Cost of Treatment with Octreotide Long-Acting Release versus Lanreotide in Patients with Metastatic Gastrointestinal Neuroendocrine Tumors

Rajeev Ayyagari, PhD, Maureen Neary, PhD, MS, Shang Li, MS, Ariel Rokito, BS, Hongbo Yang, PhD, Jipan Xie, MD, PhD, Al B. Benson III, MD, FACP, FASCO

Rajeev Ayyagari, PhD; Maureen Neary, PhD, MS; Shang Li, MS; Ariel Rokito, BS; Hongbo Yang, PhD; Jipan Xie, MD, PhD; Al B. Benson III, MD, FACP, FASCO

Practice Management

The Value of Pre–FDA Approval Healthcare Economic Information Exchange Between Payers and Drug Manufacturers

Peter R. Fendt, PharmD, MBA, Brian Ung, PharmD, RPh, F. Randy Vogenberg, PhD, FASHP

Peter R. Fendt, PharmD, MBA; Brian Ung, PharmD, RPh; F. Randy Vogenberg, RPh, PhD

Original Research, Practice Management

The Cost of Hematopoietic Stem-Cell Transplantation in the United States

Michael S. Broder, MD, MSHS, Tiffany P. Quock, MS, PhD, Eunice Chang, PhD, Sheila R. Reddy, PhD, RPh, Rajni Agarwal-Hashmi, MD, Sally Arai, MD, Kathleen F. Villa, MS

Michael S. Broder, MD, MSHS; Tiffany P. Quock, PhD, MS; Eunice Chang, PhD; Sheila R. Reddy, PhD, RPh; Rajni Agarwal-Hashmi, MD; Sally Arai, MD; Kathleen F. Villa, MS

Stakeholder Perspective

More Data Analysis Is Needed to Improve Outcomes, Lower Costs, and Maximize Appropriate Resource Use

James T. Kenney, RPh, MBA

by James T. Kenney, RPh, MBA

Original Research, Practice Management

Economic Impact of Increased Utilization of Multivariate Assay Testing to Guide the Treatment of Ovarian Cancer: Implications for Payers

Burton S. Brodsky, MD, Gary M. Owens, MD, Dennis J. Scotti, PhD, MBA, Keith A. Needham, BS, Christina L. Cool, MPH

Burton S. Brodsky, MD; Gary M. Owens, MD; Dennis J. Scotti, PhD, MBA; Keith A. Needham, BS; Christina L. Cool, MPH

Stakeholder Perspective

Economic Impact of Using Tests to Guide the Treatment of Patients with Ovarian Cancer

F. Randy Vogenberg, PhD, RPh

by F. Randy Vogenberg, PhD, FASHP

Original Research, Practice Management

Costs and Effectiveness of Mindfulness-Based Art Therapy versus Standard Breast Cancer Support Group for Women with Cancer

Katherine M. Prioli, MS, Laura T. Pizzi, PharmD, MPH, Kathryn M. Kash, PhD, Andrew B. Newberg, MD, Anna Marie Morlino, PharmD, Michael Matthews, BS, Daniel A. Monti, MD

Katherine M. Prioli, BS; Laura T. Pizzi, PharmD, MPH; Kathryn M. Kash, PhD; Andrew B. Newberg, MD; Anna Marie Morlino, PharmD; Michael J. Matthews, BS; Daniel A. Monti, MD

Stakeholder Perspective

Creative Therapeutic Activities and Support Groups Benefit All Those Involved in Cancer Care

Linda Bily, MA, CSA, OPN-CG

by Linda Bily, MA, CSA, OPN-CG

Practice Management

Value-Based Perspectives on the Management of Allergic Rhinitis

Eli O. Meltzer, MD, Don A. Bukstein, MD, Paul M. Hamrah, MS, PharmD, Nikkia Scott, PharmD, John A. Welz, MPH